Article

Transgenic expression of bean alpha-amylase inhibitor in peas results in altered structure and immunogenicity.

Division of Molecular Bioscience, The John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia.
Journal of Agricultural and Food Chemistry (impact factor: 2.82). 12/2005; 53(23):9023-30. DOI:10.1021/jf050594v
Source: PubMed

ABSTRACT The development of modern gene technologies allows for the expression of recombinant proteins in non-native hosts. Diversity in translational and post-translational modification pathways between species could potentially lead to discrete changes in the molecular architecture of the expressed protein and subsequent cellular function and antigenicity. Here, we show that transgenic expression of a plant protein (alpha-amylase inhibitor-1 from the common bean (Phaseolus vulgaris L. cv. Tendergreen)) in a non-native host (transgenic pea (Pisum sativum L.)) led to the synthesis of a structurally modified form of this inhibitor. Employing models of inflammation, we demonstrated in mice that consumption of the modified alphaAI and not the native form predisposed to antigen-specific CD4+ Th2-type inflammation. Furthermore, consumption of the modified alphaAI concurrently with other heterogeneous proteins promoted immunological cross priming, which then elicited specific immunoreactivity of these proteins. Thus, transgenic expression of non-native proteins in plants may lead to the synthesis of structural variants possessing altered immunogenicity.

0 0
 · 
0 Bookmarks
 · 
47 Views
  • Article: Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants.
    [show abstract] [hide abstract]
    ABSTRACT: The use of plants for medicinal purposes dates back thousands of years but genetic engineering of plants to produce desired biopharmaceuticals is much more recent. As the demand for biopharmaceuticals is expected to increase, it would be wise to ensure that they will be available in significantly larger amounts, on a cost-effective basis. Currently, the cost of biopharmaceuticals limits their availability. Plant-derived biopharmaceuticals are cheap to produce and store, easy to scale up for mass production, and safer than those derived from animals. Here, we discuss recent developments in this field and possible environmental concerns.
    Trends in Plant Science 06/2001; 6(5):219-26. · 11.05 Impact Factor
  • Article: Overview of the current status of genetically modified plants in Europe as compared to the USA.
    [show abstract] [hide abstract]
    ABSTRACT: Genetically modified crops have been tested in 1,726 experimental releases in the EU member states and in 7,815 experimental releases in the USA. The global commercial cultivation area of genetically modified crops is likely to reach 50 million hectares in 2001, however, the commercial production of genetically modified crops in the EU amounts to only a few thousand hectares and accounts for only some 0.03% of the world production. A significant gap exists between the more than fifty genetically modified crop species already permitted to be cultivated and to be placed on the market in the USA, Canada and other countries and the five genetically modified crop species permitted for the same use in the EU member states, which are still pending inclusion in the Common Catalogue of agricultural plant species. The further development of the "green gene technology" in the EU will be a matter of public acceptance and administrative legislation.
    Journal of Plant Physiology 08/2003; 160(7):735-42. · 2.79 Impact Factor
  • Source
    Article: Enhanced methionine levels and increased nutritive value of seeds of transgenic lupins (Lupinus angustifolius L.) expressing a sunflower seed albumin gene.
    [show abstract] [hide abstract]
    ABSTRACT: With the aim of improving the nutritive value of an important grain legume crop, a chimeric gene specifying seed-specific expression of a sulfur-rich, sunflower seed albumin was stably transformed into narrow-leafed lupin (Lupinus angustifolius L.). Sunflower seed albumin accounted for 5% of extractable seed protein in a line containing a single tandem insertion of the transferred DNA. The transgenic seeds contained less sulfate and more total amino acid sulfur than the nontransgenic parent line. This was associated with a 94% increase in methionine content and a 12% reduction in cysteine content. There was no statistically significant change in other amino acids or in total nitrogen or total sulfur contents of the seeds. In feeding trials with rats, the transgenic seeds gave statistically significant increases in live weight gain, true protein digestibility, biological value, and net protein utilization, compared with wild-type seeds. These findings demonstrate the feasibility of using genetic engineering to improve the nutritive value of grain crops.
    Proceedings of the National Academy of Sciences 09/1997; 94(16):8393-8. · 9.68 Impact Factor

Full-text

View
7 Downloads
Available from
6 May 2012

Keywords

alpha-amylase inhibitor-1
 
antigen-specific CD4+ Th2-type inflammation
 
discrete changes
 
elicited specific immunoreactivity
 
heterogeneous proteins
 
modern gene technologies
 
modified alphaAI
 
modified alphaAI concurrently
 
molecular architecture
 
native form predisposed
 
non-native host
 
non-native hosts
 
non-native proteins
 
Phaseolus vulgaris L. cv
 
Pisum sativum L
 
post-translational modification pathways
 
recombinant proteins
 
subsequent cellular function
 
transgenic expression
 
transgenic pea